EP0640097A4 - Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94). - Google Patents

Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94).

Info

Publication number
EP0640097A4
EP0640097A4 EP93911185A EP93911185A EP0640097A4 EP 0640097 A4 EP0640097 A4 EP 0640097A4 EP 93911185 A EP93911185 A EP 93911185A EP 93911185 A EP93911185 A EP 93911185A EP 0640097 A4 EP0640097 A4 EP 0640097A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
vaccination against
against coronaviruses
coronaviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93911185A
Other languages
English (en)
French (fr)
Other versions
EP0640097A1 (de
Inventor
Timothy J Miller
Sharon Klepfer
Albert Paul Reed
Elaine V Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0640097A1 publication Critical patent/EP0640097A1/de
Publication of EP0640097A4 publication Critical patent/EP0640097A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP93911185A 1992-05-08 1993-05-07 Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94). Withdrawn EP0640097A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US822171 1992-01-16
US88217192A 1992-05-08 1992-05-08
PCT/US1993/004384 WO1993023422A1 (en) 1992-05-08 1993-05-07 Compositions and methods for vaccination against coronaviruses

Publications (2)

Publication Number Publication Date
EP0640097A1 EP0640097A1 (de) 1995-03-01
EP0640097A4 true EP0640097A4 (de) 1997-01-15

Family

ID=25380027

Family Applications (2)

Application Number Title Priority Date Filing Date
EP93911170A Withdrawn EP0640096A4 (de) 1992-05-08 1993-05-07 Universelles coronavirus vakzin.
EP93911185A Withdrawn EP0640097A4 (de) 1992-05-08 1993-05-07 Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP93911170A Withdrawn EP0640096A4 (de) 1992-05-08 1993-05-07 Universelles coronavirus vakzin.

Country Status (5)

Country Link
EP (2) EP0640096A4 (de)
JP (2) JPH07508176A (de)
AU (2) AU678970B2 (de)
CA (2) CA2134898A1 (de)
WO (2) WO1993023421A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) * 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
EP0640096A4 (de) * 1992-05-08 1997-01-15 Smithkline Beecham Corp Universelles coronavirus vakzin.
PT640098E (pt) * 1992-05-08 2003-01-31 Pfizer Gene de coronavirus canino e suas utilizacoesc
EP0612532A3 (de) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Hunde Coronavirus Impfstoff aus einem Katzen-enterischen Coronavirus
AU721367B2 (en) * 1993-02-26 2000-06-29 Wyeth Holdings Corporation Canine coronavirus vaccine from feline enteric coronavirus
GB2282601B (en) * 1993-09-16 1998-04-15 Solvay Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
WO1997010347A1 (en) * 1995-09-15 1997-03-20 Howard John A Expression cassettes and methods for delivery of animal vaccines
WO1998027433A1 (en) * 1996-12-18 1998-06-25 Engene Biotechnologies, Inc A specific diagnostic for antibodies to feline infectious peritonitis virus
WO1999025838A1 (en) * 1997-11-14 1999-05-27 University Of Georgia Research Foundation, Inc. Compositions and methods to prevent turkey enteritis
WO2001009290A2 (es) * 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Serotipo de virus de bronquitis infecciosa aviar
FR2828405B1 (fr) * 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
AU2004259750A1 (en) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Soluble fragments of the SARS-CoV spike glycoprotein
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
ITMI20111182A1 (it) * 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN113248576A (zh) * 2020-02-12 2021-08-13 北京科兴中维生物技术有限公司 一种针对冠状病毒的核酸疫苗及其制备方法
US20240009297A1 (en) * 2020-07-24 2024-01-11 Soligenix, Inc. Antibody/Adjuvant Compositions and Methods of Immune Response Generation against Coronaviruses
CN113072626B (zh) * 2021-04-25 2023-05-05 龙岩学院 一种猫冠状病毒s重组蛋白及其制备方法
CN113238048B (zh) * 2021-05-11 2024-03-15 抗码(苏州)生物科技有限公司 一种诊断标志物及其在区分新冠病毒感染和新冠病毒灭活疫苗接种中的应用
CN114057894B (zh) * 2021-06-18 2022-08-05 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN114478716B (zh) * 2021-12-28 2024-05-28 梅州市人民医院(梅州市医学科学院) 一种多肽组合及其在新型冠状病毒抗体检测中的应用
CN114773487A (zh) * 2022-05-31 2022-07-22 湖南大学 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine
WO1993023423A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Canine coronavirus s gene and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63123385A (ja) * 1986-09-05 1988-05-27 デュファル・インテルナチオナル・レセールフ・ベー・ヴェー 新規抗原的活性蛋白質およびぺプチド、並びにネコ科感染性腹膜炎ウイルスワクチン
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
WO1991002752A1 (en) * 1989-08-22 1991-03-07 Veterinary Infectious Disease Organization Bovine coronavirus polypeptides and vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine
WO1993023423A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Canine coronavirus s gene and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M.J.M. KOOLEN ET AL.: "Immunogenic peptide comprising a mouse hepatitis virus A59 B-Cell epitope and an influenza virus T-cell epitope protects against lethal infection", JOURNAL OF VIROLOGY, vol. 64, no. 12, 1990, pages 6270 - 6273, XP000608291 *
See also references of WO9323422A1 *
W.P.A. POSTHUMUS ET AL.: "analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus", JOURNAL OF VIROLOGY, vol. 64, no. 7, 1990, pages 3304 - 3309, XP000608290 *

Also Published As

Publication number Publication date
CA2134898A1 (en) 1993-11-25
JPH07508176A (ja) 1995-09-14
CA2135201A1 (en) 1993-11-25
AU678971B2 (en) 1997-06-19
AU678970B2 (en) 1997-06-19
WO1993023422A1 (en) 1993-11-25
EP0640096A1 (de) 1995-03-01
AU4241093A (en) 1993-12-13
EP0640096A4 (de) 1997-01-15
EP0640097A1 (de) 1995-03-01
AU4240493A (en) 1993-12-13
JPH08501931A (ja) 1996-03-05
WO1993023421A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
EP0640097A4 (de) Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94).
EP0650370A4 (de) Auf spezifische gewebe abzielende verfahren und zusammensetzungen.
EP0647133A4 (de) Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe.
AP9300502A0 (en) Vaccine compositions
AP9400629A0 (en) Vaccine compositions
EP0604433A4 (de) Zusammensetzung und methode zur behandlung von krankheiten.
ZA929155B (en) Wound healing compositions and methods for preparing and using same.
EP0671937A4 (de) Pharmazeutische emulsionszusammensetzungen.
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
EP0596962A4 (en) Therapeutic compositions and methods.
EP0649304A4 (de) Zusammensetzung und verfahren zur verminderung von muskelabbau.
EP0656791A4 (de) Therapeutische zusammensetzungen und verfahren unter verwendung von pqq.
PL313979A1 (en) Vaccine composition
AU7008494A (en) Methods and compositions for (salmonella)-based vaccines
GB9326425D0 (en) Vaccine compositions
EP0603965A3 (en) Modified block copolymers and process for the preparation thereof.
GB9420616D0 (en) Method, compositions and use
EP0590403A3 (de) Zusammensetzung mit analgetischer Wirkung.
LTIP606A (en) Peptide compounds, method for the preparation and use thereof
ZA936861B (en) Methods and agents for combating cockroaches.
GB9202933D0 (en) Vaccines
GR3020172T3 (en) Sterilant mixture and sterilization method.
LTIP608A (en) Peptide compounds, method for the preparation and use thereof
EP0759778A4 (de) Nicht infektiöse impfstoffe
GB9524214D0 (en) Methods and compositions for hiv vaccination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER INC.

A4 Supplementary search report drawn up and despatched

Effective date: 19961128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990719

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000302